Kymera Investor Day Presentation Deck

Key Eligibility Criteria: R/R B-cell lymphoma •> 2 prior systemic regimens Ineligible or refused CAR-T or ASCT Advanced solid tumors > 2 prior systemic regimens or no available SOC ● ● KT-333: Clinical Study Design and Objectives Primary Objective: To evaluate safety, PK/PD in PTCL, CTCL, LGL-L and solid tumors ● Study Endpoints: Primary: Safety, tolerability, ● ● MTD/RP2D Secondary: PK, preliminary efficacy Exploratory: STAT3 knockdown and downstream effects in PBMC and tumor KYMERA ©2021 KYMERA THERAPEUTICS, INC. DL1 Phase 1a Dose Escalation & MTD/RP2D Expansion DL2 DLx Protocol Amendment KT-333 + SOC Combo MTD/RP2D Lymphoma Expansion MTD/RP2D Solid Tumor Expansion DL1-DLX DL1 DLx→ KYMERA R&D DAY - December 16th, 2021 MTD/RP2D Expansion MTD/RP2D Expansion Phase 1b Dose Expansion PTCL ≥1 prior systemic regimens CTCL ≥1 prior systemic regimens LGL-L ≥1 prior systemic regimens Solid Tumors Combination Expansion Combination Expansion PAGE 64

View entire presentation